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Purpose
Early aggressive therapy has been shown to result in
superior outcomes in adults with RA, but evidence for a
similar benefit has not been demonstrated in children
with JIA. The objective was to determine if aggressive
treatment initiated within the first 12 mos after onset of
extended oligoarticular (e-oligo), or RF + or (-) polyarti-
cular JIA (poly JIA) can induce inactive disease (ID)
within 6 mos (primary endpoint) and clinical remission
on medication (CRM: ID for 6 continuous mos on med-
ication; exploratory endpoint) within 1 yr of starting
therapy.
Methods
TREAT was designed as a multi-centered, prospective,
double blind, randomized, placebo controlled clinical trial
in children aged 2 to 16 yrs with e-oligo or poly JIA of ≤
12 mos duration. Participants were randomized 1:1 into
1 of 2 aggressive treatment arms: (Arm 1) MTX 0.5 mg/
kg/wk SQ (40 mg max), plus etanercept 0.8 mg/kg/wk (50
mg max), plus prednisone 0.5 mg/kg/d (60 mg max)
tapered to 0 by 17 wks or; (Arm 2) MTX (same dose as
Arm 1) plus etanercept placebo, plus prednisolone pla-
cebo, then followed on protocol for up to 12 mos. After 4
mos on therapy participants who failed to achieve at least
an ACR Pediatric 70 received open label etanercept, MTX,
and prednisolone in the same doses as Arm 1. At 6 mos
the participants who achieved ACR Pediatric 70 but failed
to achieve ID received open label medication as in Arm 1.
Efficacy analyses focused on the intent-to-treat approach.
Safety data were recorded for all participants who received
at least one dose of medication.
Results
15 centers enrolled 85 participants (64 [75%] female) with
a median age of 11.1 yrs and disease duration of 4.1 mos.
70% were ANA+, 33% RF+, and 33% anti-CCP+. At base-
line the median physician’s global assessment of disease
activity and parent global assessment of overall well-being
were 7 and 5 respectively. There were no significant inter-
Arm differences in any of these variables. At baseline,
Arm 2 had a statistically higher mean ESR (45 vs. 29 mm/
hr) and active joint count (25.5 vs. 18.9) compared to Arm
1. By 4 mos, 30 of 42 (71%) participants in Arm 1 and 19
of 43 (44%) in Arm 2 achieved an ACR Pediatric 70 (X2 =
6.5; p<.011). By 6 mos, 17 of 42 (40%) of participants in
Arm 1 achieved ID, compared to 10 of 43 (23%) in Arm 2
(X2 = 2.91; p = .088). Although all 6 ACR pediatric core
set variables showed highly significant improvement from
baseline by 6 mos in both Arms (p < .001), 5 of 6 core set
variables showed statistically greater improvement in Arm
1 vs. Arm 2. By 12 mos, 12 (14%) participants achieved
CRM; 9 (21%) had remained in Arm 1, and 3 (6%) had
remained in Arm 2 throughout the study (p = 0.0534).
There were no significant inter-arm differences in the inci-
dence of Grade 3 or higher adverse events, including infec-
tions requiring systemic therapy. There were 3 SAEs:
pneumonia (Arm 1), psychosis (open label), and bactere-
mia with septic arthritis (open label). All resolved without
sequelae.
Conclusion
Although this trial did not reach its primary endpoint,
early aggressive therapy in this cohort of children with
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severe JIA and a high rate of RF positivity resulted in
substantial proportions of participants achieving an ACR
Pediatric 70 by 4 mos, ID by 6 mos, and CRM within
12 mos of treatment initiation.
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